FibroGen Announces Outcome of FDA Advisory Committee Review of Roxadustat for Treatment of Anemia of Chronic Kidney Disease

 > Nachricht
FibroGen Announces Outcome of FDA Advisory Committee Review of Roxadustat for Treatment of Anemia of Chronic Kidney Disease
Nachrichtenquelle: globenewswire
 |  16.07.2021, 00:26  | 
102 
 | 
0 
SAN FRANCISCO, July 15, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee
(CRDAC) voted to recommend not approving roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, for the treatment of anemia due to chronic kidney disease (CKD) in adult
patients. The Committee based its recommendation on data from a global Phase 3 program encompassing more than 8,000 patients. While the FDA is not required to follow the Committee's vote, the

Related Keywords

China ,Japan ,Chile ,South Korea , ,European Medicines Agency ,Committee For Medicinal Products Human Use ,Medicinal Products ,Human Use ,சீனா ,ஜப்பான் ,சிலி ,தெற்கு கொரியா ,குழு க்கு மருத்துவ ப்ராடக்ட்ஸ் மனிதன் பயன்பாடு ,மருத்துவ ப்ராடக்ட்ஸ் ,மனிதன் பயன்பாடு ,